Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Deepak Kilari MD
Associate Professor
Department of Medicine
Division of Hematology and Oncology - Medicine

OFFICE ADDRESS:
Clinical Cancer Center
9200 W Wisconsin Ave
Milwaukee, WI 53226

EDUCATION:
09/1999 - 05/2005 M.B.B.S., Andhra Medical College, Visakhapatnam, India

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
National
Novel therapeutic targets in Prostate Cancer, Siteman Cancer Center; Washington University St Louis, Missouri, 01/2013 - Present
Alternate approaches in the treatment of men with systemic Prostate cancer, Smilow Cancer Center, Yale University, New Haven, CT, 02/2013 - Present
 


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Kilari D, Mohile SG. Management of cancer in the older adult. Clin Geriatr Med. 2012 Feb;28(1):33-49.
2. Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M. An observational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer. J Mens Health. 2012 Sep 01;9(3):182-189. PMCID: PMC3886726
3. Kilari D, Venci N, Friedberg J, Bennett JM. Hemophagocytic lymphohistiocytosis masquerading as progressive chronic lymphocytic leukemia. Leuk Res Rep. 2013;2(1):4-6. PMCID: PMC3850386
4. Kilari D, Dale W, Mohile SG. How we treat early systemic prostate cancer in older men. J Geriatr Oncol. 2014 Oct 01;5(4):337-42.
5. Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II, Siddik ZH. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer. 2014 Jul;85(1):88-93. PMCID: PMC4090351
6. Xia S, Kohli M, Du M, Dittmar RL, Lee A, Nandy D, Yuan T, Guo Y, Wang Y, Tschannen MR, Worthey E, Jacob H, See W, Kilari D, Wang X, Hovey RL, Huang CC, Wang L. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget. 2015 Jun 30;6(18):16411-21. PMCID: PMC4599278
7. Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget. 2017 Jan 10;8(2):3724-3745. PMCID: PMC5356914
8. Thompson JR, Zhu J, Kilari D, Wang L. Applications of Extracellular RNAs in Oncology. Mol Diagn Ther. 2017 02;21(1):1-11.
9. Flynn T, Guancial EA, Kilari M, Kilari D. Case Report: Spironolactone Withdrawal Associated With a Dramatic Response in a Patient With Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 02;15(1):e95-e97.
10. Kilari D, Guancial E, Kim ES. Role of copper transporters in platinum resistance. World J Clin Oncol. 2016 Feb 10;7(1):106-13. PMCID: PMC4734932
11. Abbott DW, Kilari D, Senebouttarath K, Iczkowski KA. Squamous cell carcinoma of the prostate with concomitant adenocarcinoma in the absence of prior androgen deprivation therapy Case Reports in Clinical Pathology. 2016 June 01;3(2):60-63
12. Kilari D, Soto-Perez-de-Celis E, Mohile SG, Alibhai SM, Presley CJ, Wildes TM, Klepin HD, Demark-Wahnefried W, Jatoi A, Harrison R, Won E, Mustian KM. Designing exercise clinical trials for older adults with cancer: Recommendations from 2015 Cancer and Aging Research Group NCI U13 Meeting. J Geriatr Oncol. 2016 07;7(4):293-304. PMCID: PMC4969104
13. Guancial EA, Kilari D, Xiao GQ, Abu-Farsakh SH, Baran A, Messing EM, Kim ES. Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. PLoS One. 2016;11(5):e0155503. PMCID: PMC4871463
14. Presley CJ, Dotan E, Soto-Perez-de-Celis E, Jatoi A, Mohile SG, Won E, Alibhai S, Kilari D, Harrison R, Klepin HD, Wildes TM, Mustian K, Demark-Wahnefried W. Gaps in nutritional research among older adults with cancer. J Geriatr Oncol. 2016 07;7(4):281-92. PMCID: PMC4969118
15. Kilari D, Iczkowski KA, Pandya C, Robin AJ, Messing EM, Guancial E, Kim ES. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients. Anticancer Res. 2016 Feb;36(2):495-501.
16. Raychaudhuri R, Riese MJ, Bylow K, Burfeind J, Mackinnon AC, Tolat PP, Iczkowski KA, Kilari D. Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm. Clin Genitourin Cancer. 2017 10;15(5):e897-e901.
17. Du M, Giridhar KV, Tian Y, Tschannen MR, Zhu J, Huang CC, Kilari D, Kohli M, Wang L. Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer. Oncotarget. 2017 Sep 08;8(38):63703-63714. PMCID: PMC5609954
18. Kapke J, Shaheen Z, Kilari D, Knudson P, Wong S. Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management. Case Rep Oncol. 2017 Sep-Dec;10(3):897-909. PMCID: PMC5731100
19. Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L. Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. Prostate Cancer Prostatic Dis. 2018 09;21(3):411-418. PMCID: PMC6126974
 
Abstracts
1. Kilari D, Carmel R, Dosik, H, Bellevue. Priapism: the first manifestation of Sickle cell trait. Poster presentation at the Society of General Internal Medicine (SGIM) annual meeting, 2008 May 01;Pittsburgh, PA.
2. Kilari D, Chakraborty S, Politsmakher A, Carmel R, Dosik, Hassan, S. Use of Advanced Care Directives by Ambulatory Chemotherapy Patients with various malignancies. Poster presentation at the New York Methodist Hospital (NYMH) Annual Research Retreat, 2009, New York, NY.
3. Kilari D, Carmel R, Gerecitano J. Methotrexate-related Lymphoproliferative disorders. Poster Presentation at the New York Chapter of American College of Physicians (NYACP) Annual Meeting 2009; New York, NY
4. Haque M, Kilari D, Bellevue R, Dosik H. Chronic Myeloid leukemia (CML) in a patient with sickle cell disease, Poster Presentation at the New York Methodist Hospital Resident Research day: Annual meeting, 2010 New York, NY.
5. Ninan N, Wentowski C, Sudore P, Abdelwahed A, Kilari D, Bellevue R, George L, MD. The Association Between Lipid Levels and Pulmonary Hypertension in Patients With Sickle Cell Disease. Poster presented at the American College of Chest Physicians (ACCP), Annual Meeting, 2010, Vancouver, British Columbia.
6. Kilari D, Pandya C, Fung C, Sahasrabudhe D, Brasacchio RA, Messing EM, Sievert L, Gupta SM; Characteristics and Outcomes of the elderly patients treated with peripheral androgen blockade. Poster presented at the Genitourinary American Society of Clinical Oncology (GU- ASCO), Annual Meeting, 2013, Orlando, Florida. J Clinical Oncology 31, 2013 (suppl 6; abstract 226)
7. Kilari D, Yao J, Scosyrev E, Evans EE, Sahasrabudhe DM; C35 a new prognostic tool and potential therapeutic target in patients with Prostate cancer. Poster presented at the Genitourinary American Society of Clinical Oncology (GU- ASCO), Annual Meeting, 2013, Orlando, Florida. J Clinical Oncology 31, 2013 (suppl 6; abstract 212)
8. Kilari D, Pandya C, Fung C, Sahasrabudhe D, Brasacchio RA, Messing EM, Sievert L, Gupta SM; The role of Comprehensive Geriatric Assessment (CGA) in identifying Elderly patients with Systemic Prostate Cancer (PCa) for Peripheral Androgen Blockade (PAB). Poster presented at the American Geriatric Society, annual meeting 2013. Grapevine, Texas.
9. Kilari D, Tang X, Chow C, Fujimoto J, Kalhor N, Swisher S, Wistuba I, Stewart DJ, Siddik ZH, Kim ES, Copper transporter expression (CTR1) and tissue platinum concentration in Non-small cell lung cancer. Poster Presented at the American Society of Clinical Oncology (ASCO), Annual Meeting, 2013, Chicago, IL. J Clinical Oncology 31, 2013 (suppl; abstract 2601)
10. Guancial E, Kilari D, Messing EM, Kim ES; Platinum concentration in bladder tissue treated with neoadjuvant chemotherapy and pathologic response. Poster Presented at the Genitourinary American Society of Clinical Oncology (GU- ASCO), Annual Meeting, 2015, San Francisco, CA. J Clinical Oncology 33, 2015 (suppl 7; abstract 341)
11. Kilari D, Iczkowski KA, Robin A, Pandya C, Messing EM, Guancial EA, Kim ES. Association between Copper Transporter Receptor 1(CTR1) Expression and Pathologic Outcomes in Platinum (Pt)-treated Bladder Cancer (BC) patients. Presented at the European Cancer Congress, annual meeting 2015, Vienna Austria.
12. Kilari D, Guancial E, Sahasrabudhe D, Bylow D, Burfeind J, Musto K, Feng C, Messing E, Mohile SG, Fung C.A Phase II Study of Enzalutamide (Enz) with Dutasteride (Dut) or Finasteride (Fin) in Men ≥ 65 Years with Hormone-naive Systemic Prostate Cancer (HNSPCa). Poster at GU ASCO, Feb 2017, Orlando, FL.
13. S Ramalingam, A Szabo, D Kilari, C Bhosekar, J Karpinski, SWong; Mannitol Enhances Cumulative Cisplatin Dose by Protecting against Cisplatin-Induced Nephrotoxicity Poster at ASCO 2017.
14. J. F. Borkenhagen, D. Eastwood, D. Kilari, W. A. See, J. D. Van Wickle, C. A. Lawton, W. A. Hall Prognostic Value of Clinical Stage T2 Substages in Prostate Cancer: A National Cancer Database Review. Poster at ASTRO 2017.
15. W. A. Hall, D Eastwood, D Kilari, J Wickle, R Raychaudhuri, J Borkenhagen, W See, C Lawton Androgen Deprivation Therapy (ADT) and Radiation Therapy (RT) Alone As Compared with Trimodality Therapy With ADT, RT, and Surgery In Men With High Risk, Non-Metastatic Adenocarcinoma Of The Prostate: Oral presentation at ASTRO 2017.
16. D Kilari, E Guancial2, D Sahasrabudhe, S Mohile, C Fung. Phase II Study of Enzalutamide (Enz) with Dutasteride (Dut) or Finasteride (Fin) in Men ≥ 65 Years with Hormone-naive Systemic Prostate Cancer (HNSPCa): Updated analysis: Poster at ESMO Madrid, Spain 2017.
17. A. Singavi, S. Menon, D. Kilari, A. Alqwasmi, P.S. Ritch, J.P. Thomas, A.L. Martin, C. Oxencis, S. Ali, B. George. Predictive biomarkers for Hyper-progression (HP) in response to Immune Checkpoint Inhibitors (ICI) – Analysis of Somatic Alterations (SAs) Poster at ESMO Madrid, Spain 2017.
18. D Kilari, P Hari, M Qayed, R Fraser, O Davila, S Kumar, TM Mark, Y Nieto, A D'Souza; Tandem high dose chemotherapy and autologous hematopoietic stem cell transplantation (SCT) is superior to single SCT for relapsed/refractory germ cell tumors (GCT). Poster at GU ASCO Feb 2018, San Francisco, California.
19. D. Petrylak, D. Smith, T.W. Flaig, J. Zhang, S.S. Sridhar, J. Ruether, E. Plimack, J. Merchan, D. Quinn, D. Kilari, S. Srinivas, J. Baranda, J. Lang, M. Milowsky, M. Galsky, A. Spira, E. Gartner, C. Wu, A. Melhem-Bertrandt, J.E. RosenbergEnfortumab Vedotin in Patients with Metastatic Urothelial Carcinoma with Prior Checkpoint Inhibitor Failure: A Prospective Cohort of an Ongoing Phase 1 Study. Poster at GU ASCO Feb 2018, San Francisco, California.
20. R Raychaudhuri, K Bylow, W Lea, T Zellmer, K Musto, J Burfeind, M Riese, D Kilari Liver-Directed Therapy (LDT) for Metastatic Renal Cell Carcinoma (mRCC): Single center experience. Poster at GU ASCO Feb 2018, San Francisco, California.
21. K. Bylow, D Kilari, M Riese, J Burfeind, M Stolley, R Prost, K Musto, R Neilson, A Szabo, J Thomas, AV. Ng, Effect of β-hydroxy-β-methyl butyrate (HMB) on muscle strength in older men with prostate cancer (PCA) started on androgen deprivation therapy (ADT): Preliminary results of an open-label, randomized trial. Poster, GU ASCO Feb 2018 San Francisco, California.
22. Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz MA, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hildebrandt GC, Holmberg L, Kamble RT, Kapoor P, Lazarus H, Lee C, Murthy HS, Naik S, Nishihori T, Saad A, Savani BN, Seo S, Warwick A, Wirk B, Yared JA, Nieto Y, Hari P. Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biol Blood Marrow Transplant. 2019 06;25(6):1099-1106. PMCID: PMC6559839
23. Robbins JR, Kilari D, Johnston F. Palliative care education for oncologists: how are we doing? Ann Palliat Med. 2019 Sep;8(4):364-371.
24. Borkenhagen JF, Eastwood D, Kilari D, See WA, Van Wickle JD, Lawton CA, Hall WA. Digital Rectal Examination Remains a Key Prognostic Tool for Prostate Cancer: A National Cancer Database Review. J Natl Compr Canc Netw. 2019 Jul 01;17(7):829-837.
25. Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M. An observational study of plasma vascular endothelial growth factors (vegf) a and d expression in non-localized prostate cancer Journal of Men's Health. September 2012;9(3):182-189.
26. Udhane V, Maranto C, Hoang DT, Gu L, Erickson A, Devi S, Talati PG, Banerjee A, Iczkowski KA, Jacobsohn K, See WA, Mirtti T, Kilari D, Nevalainen MT. Enzalutamide Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. Mol Cancer Ther. 2019 Sep 23.
 

jenkins-FCD Prod-410 e9586552fe7f53c71f7923aa6e27aeabbd3c2473